HUVY is a SaaS platform designed for primary healthcare professionals, enabling the analysis of pigmented lesions from dermoscopic photographs using a deep learning AI trained on nearly 100,000 images. In less than 15 seconds, the tool assesses the risk of melanoma with high clinical performance (96–100% sensitivity, ~70% specificity), validated by multiple studies, including real-world clinical conditions with Nantes University Hospital.
Positioned as a rapid triage test (a screening and referral aid, not a diagnostic device), the solution integrates prior to the dermatological consultation to optimize patient triage: expediting the management of at-risk cases while preventing unnecessary referrals. HUVY is committed to a rigorous CE Class IIb certification pathway and an approach focused on clinical robustness, transparency, and collaboration with healthcare providers.
The expected benefits are manifold: enhanced early detection, reduction of diagnostic delays, alleviation of dermatologist backlogs, and improved access to screening, including in medically underserved areas. The fundraising round planned for 2025 aims to support large-scale deployment across France and subsequently Europe, with the ambition of establishing HUVY as a leading authority in dermatology AI.




